In this episode, Naval G. Daver, MD, discusses promising investigational agents and treatment combinations in clinical trials for patients with newly diagnosed and relapsed/refractory AML, including:

• FLT3 inhibitors crenolanib and quizartinib
• Anti-CD47 antibody magrolimab
• IMGN632, a CD123 antibody–drug conjugate
• Anti-CD70 antibody cusatuzumab
• APR-246, targeting the TP53 mutation

Content is part of an online CME program supported by an educational grant from Daiichi-Sankyo.

Link to full program, including a ClinicalThought commentary:  https://bit.ly/2Y2uCG2

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.